🇺🇸 FDA
Pipeline program

Mitoxantrone Hydrochloride Liposome

CSPC-DED-AML-K23

Phase 3 small_molecule active

Quick answer

Mitoxantrone Hydrochloride Liposome for Acute Myeloid Leukemia (AML) is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Acute Myeloid Leukemia (AML)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials